ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
Boehringer Ingelheim inks $870M worth deal with Yuhan Corp biospectrumasia
July 04, 2019Boehringer Ingelheim and Yuhan Corporation have announced a collaboration and license agreement for the development of a first-in-class dual agonist for the treatment of NASH and related liver diseases that combines GLP-1 and FGF21 activity in one molecul
Pharma Sources Insight January 2025
